Tag:
antibodies
Latest Headlines
Latest Headlines
Geneva Foundation gets $3M NIH grant for Ebola drug work
The Geneva Foundation, along with partner BioFactura, received a grant of more than $3 million from the U.S. National Institutes of Health to develop an antibody drug to combat the Sudan strain of the ebolavirus.
ZMapp antibody therapy prevents Ebola infection in monkeys
The drug, a combination of three monoclonal antibodies, has so far been given to 7 patients in the current Ebola outbreak.
Biomarker could improve early rheumatoid arthritis diagnosis
A novel biomarker could make it easier for physicians to diagnose rheumatoid arthritis early, thereby improving patients' prospects. The best results come when conventional antibody testing is combined with the new biomarker.
MorphoSys bets on Emergent BioSolutions' cancer contender in $183M deal
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
Janssen rethinks drug discovery in a changing R&D environment
For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.
Scripps, U. of Nebraska-Lincoln win $15M to advance HIV vaccines
The Scripps Research Institute has landed a $13 million grant from the National Institute of Allergy and Infectious Diseases to advance antibodies toward the development of an HIV vaccine. Meanwhile, another team of researchers at the University of Nebraska-Lincoln has won nearly $2 million for its experimental HIV vaccine.
Antigen discovery could advance malaria vaccine
In a discovery that could put a vaccine for malaria closer in sight, scientists have linked a protein to an essential function in malaria-causing parasites that enables them to escape from inside red blood cells and infect the rest of the body.
Tesaro pays $17M to team with AnaptysBio on cancer immunotherapies
Tesaro is making a move into the hot cancer immunotherapy field, paying $17 million upfront and offering milestones worth hundreds of millions more to work with AnaptysBio on a portfolio of antibodies that could be used in combination with its own pipeline drugs. And while one of the targets is PD-1, a popular subject in a field now dominated by Bristol-Myers Squibb and Merck, a pair of less familiar targets is also included in the package.
Antibody discovery opens new avenue for HIV vaccine development
A team of U.S. and South African researchers has identified and cloned an antibody that targets one of the few unchanging regions of HIV.
Investigators ID a rare antibody that may offer a key to elusive HIV vaccine
For several years now, scientists working on an HIV vaccine have been focused on a small set of patients whose immune systems were able to generate rare antibodies able to vanquish most strains of the lethal virus. And over the weekend a team of scientists from South Africa and the U.S. say that one woman--dubbed CAP256-VRC26--may have offered a key to do just that.
